Global cholesterol-lowering drugs market to rise by $23 billion, says Visiongain

Growth of $23 billion by the year 2021 is anticipated in the global cholesterol-lowering drugs market, according to a new report from business intelligence provider, Visiongain.

The 181-page report provides analysis and insight into the global cholesterol-lowering drugs market, including revenue forecasts from 2017–2027, which are broken into four main segments: Statins and fixed-dose combinations; cholesterol absorption inhibitors, ion exchange resins, fibrates; PCSK9 inhibitors; and novel cholesterol-lowering drugs.

“Visiongain believes the major drivers of growth in the global cholesterol-lowering drugs market will be: increasing demand for cholesterol-lowering drugs due to population growth and the increasing prevalence of high cholesterol, improvements in the management and treatment of high cholesterol, increasing healthcare expenditure, especially in a number of emerging economies and he launch of new drugs such as PCSK9 inhibitors,” commented the lead analyst of the report.

With rapid growth being seen in various markets, such as BRIC, higher rates of cholesterol are being reported — which can be attributed to shifts in diet and lifestyle choices as a result of increasing wealth — and as such giving rise to a higher demand for cholesterol-lowering treatments.

Additionally, there are numerous patents within the cholesterol-lowering drug sector that are nearing expiration or have already expired. This means that generic alternatives are becoming more prevalent — particularly true with statins.

According to Visiongain’s report there is a strong pipeline for cholesterol-lowering drugs, many of which will launch within the next two/three years. New treatments, such as PCSK9 inhibitors will enable expansion into new areas of treatment as they allow patients with very high cholesterol levels to be treated. These new treatments will lead to a significant rise in global revenues.